Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
Top Page
Mangalam Drugs & Organics Ltd.
(MANGALAM)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹29.00
▼(-4.61% Downside)
Action:ReiteratedDate:02/06/26
The score is held back primarily by weak technicals (below key long-term averages with soft momentum) and a negative P/E that limits valuation support. Financial performance is mixed: profitability and revenue recently deteriorated, but leverage appears manageable and operating cash flow has improved, preventing a lower score.
Positive Factors
Manageable leverage and stable balance sheet
A balanced debt-to-equity and consistent shareholders' equity provide financial stability that supports operations through revenue volatility. Manageable leverage preserves flexibility for capex or working capital, lowering refinancing risk and enabling durable execution of strategy over months.
Negative Factors
Declining revenue and margins
Sustained revenue and margin deterioration undermines internal funding for R&D, quality compliance and customer support. Contracting EBIT/EBITDA margins pressure profitability, reduce buffer against input cost swings, and erode competitiveness if not reversed over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage and stable balance sheet
A balanced debt-to-equity and consistent shareholders' equity provide financial stability that supports operations through revenue volatility. Manageable leverage preserves flexibility for capex or working capital, lowering refinancing risk and enabling durable execution of strategy over months.
Read all positive factors
Mangalam Drugs & Organics Ltd. (MANGALAM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹459.97M
Dividend YieldN/A
Average Volume (3M)5.11K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-24.55%
EPS Growth-310.57%
CountryIN
Employees432
SectorBasic Materials
Sector Strength58
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-6.21
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.84
Price to Sales (P/S)0.39
P/FCF Ratio5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mangalam Drugs & Organics Ltd. Business Overview & Revenue Model
Company Description
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for ...
How the Company Makes Money
Mangalam Drugs & Organics Ltd. primarily makes money by manufacturing and selling its chemical and pharmaceutical intermediate products to business customers (B2B). Revenue is generated from (1) domestic sales to Indian customers and (2) export sa...
Mangalam Drugs & Organics Ltd. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
65
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.68B | 3.18B | 3.67B | 3.70B | 4.47B | 3.80B |
| Gross Profit | 1.03B | 1.50B | 188.12M | 287.77M | 546.89M | 976.69M |
| EBITDA | 112.23M | 363.25M | 174.95M | 259.54M | 451.84M | 550.15M |
| Net Income | -197.98M | 67.21M | -90.72M | 12.70M | 196.57M | 279.71M |
Balance Sheet | ||||||
| Total Assets | 3.17B | 3.66B | 3.34B | 3.60B | 3.28B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 96.75M | 25.89M | 11.87M | 26.88M | 19.55M | 5.92M |
| Total Debt | 949.21M | 962.30M | 1.07B | 885.47M | 879.04M | 697.06M |
| Total Liabilities | 1.89B | 2.17B | 1.98B | 2.08B | 1.78B | 1.33B |
| Stockholders Equity | 1.28B | 1.49B | 1.36B | 1.52B | 1.51B | 1.31B |
Cash Flow | ||||||
| Free Cash Flow | 19.14M | 223.93M | -79.20M | 116.09M | -19.60M | -38.86M |
| Operating Cash Flow | 77.10M | 425.94M | 39.13M | 395.23M | 257.09M | 275.50M |
| Investing Cash Flow | -57.59M | -194.72M | -118.27M | -221.72M | -273.26M | -312.85M |
| Financing Cash Flow | -11.63M | -217.12M | 52.27M | -166.17M | 29.79M | 26.98M |
Mangalam Drugs & Organics Ltd. Technical Analysis
Negative
30.40
Price Trends
33.92
Negative
35.33
Negative
56.83
Negative
Market Momentum
-1.14
Positive
42.32
Neutral
33.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANGALAM, the sentiment is Negative. The current price of 30.4 is below the 20-day moving average (MA) of 30.56, below the 50-day MA of 33.92, and below the 200-day MA of 56.83, indicating a bearish trend. The MACD of -1.14 indicates Positive momentum. The RSI at 42.32 is Neutral, neither overbought nor oversold. The STOCH value of 33.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANGALAM.
Mangalam Drugs & Organics Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹6.44B | 17.61 | ― | 0.81% | 33.39% | 85.08% | |
63 Neutral | ₹5.69B | 9.06 | ― | ― | -12.30% | -26.40% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹4.98B | 9.32 | ― | ― | 67.43% | ― | |
58 Neutral | ₹2.89B | 58.29 | ― | 0.94% | 13.33% | -21.39% | |
54 Neutral | ₹3.34B | 24.26 | ― | ― | 22.53% | 237.55% | |
50 Neutral | ₹459.97M | -1.11 | ― | ― | -24.55% | -310.57% |
* Basic Materials Sector Average
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
29.06
-48.94
-62.74%
IN:BHAGERIA
Bhageria Industries Ltd.
147.45
-8.55
-5.48%
IN:GANESHBE
Ganesh Benzoplast Limited
79.06
-44.24
-35.88%
IN:HPAL
HP Adhesives Ltd.
31.49
-20.47
-39.40%
IN:KHAICHEM
Khaitan Chemicals & Fertilizers Ltd.
51.38
3.21
6.66%
IN:MANORG
Mangalam Organics Ltd
389.65
-16.35
-4.03%
Mangalam Drugs & Organics Ltd. Corporate Events
Mangalam Drugs & Organics Closes Trading Window Ahead of FY26 Results
Mar 24, 2026
Mangalam Drugs Organics Ltd. has announced the closure of its trading window for designated persons and their immediate relatives from April 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s int...
Mangalam Drugs & Organics Reshuffles Board, Appoints New CFO
Feb 6, 2026
Mangalam Drugs Organics Limited’s board met on 6 February 2026 and approved several key changes in its leadership structure and governance. The board accepted the resignation of independent director Rukmesh P. Dhandhania with effect from 16...
Mangalam Drugs & Organics Posts Quarterly Loss in Unaudited Results for December 2025
Jan 16, 2026
Mangalam Drugs Organics Ltd. has published its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, following approval by its board on 15 January 2026 and subsequent newspaper publication...
Mangalam Drugs & Organics CFO and Company Secretary Resign as Board Clears Quarterly Results
Jan 15, 2026
Mangalam Drugs Organics Ltd. has announced that its Board of Directors, at a meeting held on 15 January 2026, approved the company’s unaudited standalone and consolidated financial results for the quarter ended 15 January 2026, with the sta...
Mangalam Drugs Files SEBI Demat Compliance Certificate for December Quarter
Jan 12, 2026
Mangalam Drugs Organics Limited has submitted to both BSE and NSE a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The certificate, issued by it...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.